Buildings and Landmarks Join LRF to Light Red and Raise Awareness for Blood Cancer Awareness Month
The tenth anniversary of the Lymphoma Research Foundation’s Blood Cancer Awareness Month initiative expected to reach millions.
The tenth anniversary of the Lymphoma Research Foundation’s Blood Cancer Awareness Month initiative expected to reach millions.

Foundation to Celebrate Achievements of Honorees AstraZeneca, Thomas M. Habermann, MD and Heroes Among the Lymphoma Community

A multi-stakeholder working group recommends consistent biomarker, genetic and genomic testing terminology for patient education and clinical care.

LRF celebrates 25 years of innovation and progress with global awareness and fundraising campaign.

Projects awarded from this year’s class of CDA and Postdoctoral Fellows include early clinical trials of novel therapies, investigations into the biology of Hodgkin lymphoma and aggressive non-Hodgkin lymphomas, and new mechanisms
for chimeric antigen receptor (CAR) T cell therapy.

Five years ago, Jacqueline Gates and John Groskopf were strangers; they would soon discover they shared a rare similarity that would connect them forever.

On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…

Lymphoma Research Foundation Elects Allison+Partners Co-Founder Scott Pansky to Esteemed Board

The American Board of Internal Medicine (ABIM) has ABIM has 12 Specialty Boards - one for all disciplines solely sponsored and administered by ABIM. The Specialty Boards are where the frontline work at the discipline-specific level is done.

Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.